Description: Discussion of methods to estimate unpaid claim liability UCL for health plans. Includes traditional IBNR lag method and a lag method based on claims reported but not paid RBNP. Issue No. 45

Description: This article describes employer considerations when evaluating Private Exchanges and potential financial impacts of a multi-carrier, fully-insured model

Description: The coming wave of biosimilars could dramatically affect prescription drug costs and benefit strategies over the next several years. The launch of many Humira biosimilars in 2023 is the Big Event that will largely determine the impact of the biosimilar wave. Payers have many decisions to make about coverage and formulary tiers. What factors will drive payer decision-making?

Description: The coming wave of biosimilars could have a major impact on prescription drug spend in coming years. The big event of Humira biosimilar launches in 2023 will be significant in determining that ultimate impact. Payers are making coverage decisions. The more biosimilars are utilized, the greater the potential savings. How will biosimilar adoption be maximized?

Description: A look back at 2024, reviewing and highlighting the things that the SOA Health Section Council accomplished, including education, research, webcasts, networking, and a new Health Section Council action plan that will be used on an ongoing basis to target, track, and measure areas of focus for the council, to better serve membership.

Description: A brief review of the 2024 SOA Health Meeting in Baltimore

Description: This article provides information on the 2025 SOA Health Meeting, including how to submit a proposal, key dates, and other relevant information.

Description: Analysis of diagnosis and pharmacy-based methods of health risk assessment. Issue No. 44.

Description: The impact of Medicare on retiree medical. Issue No. 44.

Description: The impact of Medicare payments on retiree medical. Issue No. 46.